Tositumomab

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (17:01, 12 December 2010) (edit) (undo)
 
(5 intermediate revisions not shown.)
Line 1: Line 1:
===Pharmacokinetics===
===Pharmacokinetics===
-
{| class="wikitable" border="1" width="52%" style="text-align:center"
+
{| class="wikitable" border="1" width="60%" style="text-align:center"
|-
|-
-
! colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]
+
! colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmacokinetics]] <ref>GlaxoSmithKline: Study No.: Hx-CD20-402</ref>
|-
|-
! Parameter
! Parameter
Line 10: Line 10:
! Ibritumomab
! Ibritumomab
|-
|-
-
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
+
! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
! Tositumomab
! Tositumomab
-
! Ofatumumab
+
! 7.6
! Rituximab
! Rituximab
! Ibritumomab
! Ibritumomab
|-
|-
-
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
+
! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
! Tositumomab
! Tositumomab
-
! Ofatumumab
+
! 167000
-
! Rituximab
+
! 205800
-
! Ibritumomab
+
! 67000
|-
|-
-
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
+
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
! Tositumomab
! Tositumomab
! Ofatumumab
! Ofatumumab
Line 28: Line 28:
! Ibritumomab
! Ibritumomab
|-
|-
-
! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)
+
! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
-
! Tositumomab
+
! 64.8
-
! Ofatumumab
+
! 68
-
! Rituximab
+
! 206
-
! Ibritumomab
+
! 108
|-
|-
-
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
+
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
! Tositumomab
! Tositumomab
-
! Ofatumumab
+
! 32939000
! Rituximab
! Rituximab
-
! Ibritumomab
+
! 17000
|-
|-
-
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
+
! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h)
-
! Tositumomab
+
! .078
-
! Ofatumumab
+
! .017
-
! Rituximab
+
! .009
! Ibritumomab
! Ibritumomab
|-
|-
-
! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h)
+
! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
! Tositumomab
! Tositumomab
! Ofatumumab
! Ofatumumab
Line 52: Line 52:
! Ibritumomab
! Ibritumomab
|-
|-
-
! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
+
! Dosage
! Tositumomab
! Tositumomab
-
! Ofatumumab
+
! 500 mg (4th Infusion)
-
! Rituximab
+
! 325 mg/m<sup>2</sup> (4th Infusion)
-
! Ibritumomab
+
-
|-
+
-
! Dosage (mg)
+
-
! Tositumomab
+
-
! Ofatumumab
+
-
! Rituximab
+
! Ibritumomab
! Ibritumomab
|-
|-

Current revision

Pharmacokinetics

Anti-CD20 Monoclonal Antibody Pharmacokinetics [1]
Parameter Tositumomab Ofatumumab Rituximab Ibritumomab
Tmax (hr) Tositumomab 7.6 Rituximab Ibritumomab
Cmax (ng/ml) Tositumomab 167000 205800 67000
Bioavailability (%) Tositumomab Ofatumumab Rituximab Ibritumomab
T1/2 (hr) 64.8 68 206 108
AUC (ng/ml/hr) Tositumomab 32939000 Rituximab 17000
Clearance (L/h) .078 .017 .009 Ibritumomab
IC50 (nM) Tositumomab Ofatumumab Rituximab Ibritumomab
Dosage Tositumomab 500 mg (4th Infusion) 325 mg/m2 (4th Infusion) Ibritumomab
Metabolism Tositumomab Ofatumumab Rituximab Ibritumomab

Proteopedia Page Contributors and Editors (what is this?)

David Canner

Retrieved from "http://52.214.119.220/wiki/index.php/Tositumomab"
Personal tools